Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Nadal

Showing results (71-80 of 79) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 79 results.
British Journal of Cancer|March 1, 1988
In vitro biochemical and in vivo biological studies of the uridine 'rescue' of 5-fluorouracilG J Peters, J van Dijk, E Laurensse, et al.
Cancer Research|August 1, 1990
In vivo inhibition of the pyrimidine de novo enzyme dihydroorotic acid dehydrogenase by brequinar sodium (DUP-785; NSC 368390) in mice and patientsG J Peters, G Schwartsmann, J C Nadal, et al.
Journal of Cellular Biochemistry|August 1, 1989
Purification and partial characterization of a hepatocyte antiproliferative glycopeptideG Auger, D Blanot, J van Heijenoort, et al.
HIV Medicine|June 4, 2009
Impact of prior pneumococcal vaccination on clinical outcomes in HIV-infected adult patients hospitalized with invasive pneumococcal diseaseA Imaz, V Falcó, M Peñaranda, et al.
Actas Dermo-Sifiliograficas|March 7, 2019
Spanish Consensus Document on the Treatment Algorithm for RosaceaM Salleras, M Alegre, V Alonso-Usero, et al.
Scientific Reports|February 24, 2019
Combination of KIR2DS4 and FcγRIIa polymorphisms predicts the response to cetuximab in KRAS mutant metastatic colorectal cancerA Borrero-Palacios, A Cebrián, M T Gómez Del Pulgar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 4, 2026
Erratum: VIKTORIA-1 Trial of Gedatolisib Plus Fulvestrant With or Without Palbociclib in Hormone Receptor-Positive/HER2-/PIK3CA Wild-Type Advanced Breast CancerSara A Hurvitz, Rachel M Layman, Giuseppe Curigliano, et al.
Scientific Reports|May 18, 2019
Author Correction: Combination of KIR2DS4 and FcγRIIa polymorphisms predicts the response to cetuximab in KRAS mutant metastatic colorectal cancerA Borrero-Palacios, A Cebrián, M T Gómez Del Pulgar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 9, 2026
VIKTORIA-1 Trial of Gedatolisib Plus Fulvestrant With or Without Palbociclib in Hormone Receptor-Positive/HER2-/PIK3CA Wild-Type Advanced Breast CancerSara A Hurvitz, Rachel M Layman, Giuseppe Curigliano, et al.
Pageof 8

Showing results (71-80 of 79) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 79 results.
British Journal of Cancer|March 1, 1988
In vitro biochemical and in vivo biological studies of the uridine 'rescue' of 5-fluorouracilG J Peters, J van Dijk, E Laurensse, et al.
Cancer Research|August 1, 1990
In vivo inhibition of the pyrimidine de novo enzyme dihydroorotic acid dehydrogenase by brequinar sodium (DUP-785; NSC 368390) in mice and patientsG J Peters, G Schwartsmann, J C Nadal, et al.
Journal of Cellular Biochemistry|August 1, 1989
Purification and partial characterization of a hepatocyte antiproliferative glycopeptideG Auger, D Blanot, J van Heijenoort, et al.
HIV Medicine|June 4, 2009
Impact of prior pneumococcal vaccination on clinical outcomes in HIV-infected adult patients hospitalized with invasive pneumococcal diseaseA Imaz, V Falcó, M Peñaranda, et al.
Actas Dermo-Sifiliograficas|March 7, 2019
Spanish Consensus Document on the Treatment Algorithm for RosaceaM Salleras, M Alegre, V Alonso-Usero, et al.
Scientific Reports|February 24, 2019
Combination of KIR2DS4 and FcγRIIa polymorphisms predicts the response to cetuximab in KRAS mutant metastatic colorectal cancerA Borrero-Palacios, A Cebrián, M T Gómez Del Pulgar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 4, 2026
Erratum: VIKTORIA-1 Trial of Gedatolisib Plus Fulvestrant With or Without Palbociclib in Hormone Receptor-Positive/HER2-/PIK3CA Wild-Type Advanced Breast CancerSara A Hurvitz, Rachel M Layman, Giuseppe Curigliano, et al.
Scientific Reports|May 18, 2019
Author Correction: Combination of KIR2DS4 and FcγRIIa polymorphisms predicts the response to cetuximab in KRAS mutant metastatic colorectal cancerA Borrero-Palacios, A Cebrián, M T Gómez Del Pulgar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 9, 2026
VIKTORIA-1 Trial of Gedatolisib Plus Fulvestrant With or Without Palbociclib in Hormone Receptor-Positive/HER2-/PIK3CA Wild-Type Advanced Breast CancerSara A Hurvitz, Rachel M Layman, Giuseppe Curigliano, et al.
Pageof 8